PMID- 11521731
OWN - NLM
STAT- MEDLINE
DCOM- 20020130
LR  - 20220317
IS  - 0923-7534 (Print)
IS  - 0923-7534 (Linking)
VI  - 12 Suppl 1
DP  - 2001
TI  - Current use of HER2 tests.
PG  - S97-100
AB  - Reliable detection of HER2 overexpression is important for the success of 
      trastuzumab (Herceptin) therapy. Several methods are available for measuring HER2 
      expression at the DNA, RNA or protein level. The method most frequently employed 
      is immunohistochemical (IHC) detection of the HER2 receptor in paraffin sections. 
      Advantages include the precise localization of the HER2 protein, the availability 
      of paraffin material and the ease of the procedure. However, IHC can be 
      influenced by the sensitivity/specificity of the antibody, tissue treatment and, 
      in particular, subjective assessment. These disadvantages do not exist in the 
      detection of gene amplification by fluorescence in situ hybridization (FISH) or 
      polymerase chain reaction. However, FISH requires expensive equipment that is not 
      widely available in pathology laboratories. Another approach quantitates shed 
      HER2 antigen in the serum by an enzyme-linked immunosorbent assay. The key 
      advantage of this method is the ease of sampling blood, however, serum HER2 
      concentrations do not accurately reflect the tumor status. Furthermore, this 
      method does not register single-cell expression, which is important for 
      therapeutic decision making. For routine diagnostics, the combination of IHC and 
      FISH is useful. In addition to improving the accuracy and comparability of HER2 
      assays, these optimized protocols may further enhance the efficacy of trastuzumab 
      therapy by selecting those patients most likely to respond.
FAU - Schaller, G
AU  - Schaller G
AD  - Frauenklinik, Universitatsklinikum Benjamin Franklin, Berlin, Germany. 
      schaller@ukbf.fu-berlin.de
FAU - Evers, K
AU  - Evers K
FAU - Papadopoulos, S
AU  - Papadopoulos S
FAU - Ebert, A
AU  - Ebert A
FAU - Buhler, H
AU  - Buhler H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (RNA, Neoplasm)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/*chemistry/*diagnosis/genetics
MH  - DNA, Neoplasm/analysis
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Gene Amplification
MH  - Gene Expression Regulation, Neoplastic
MH  - Genes, erbB-2/*genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Polymerase Chain Reaction
MH  - Prognosis
MH  - RNA, Neoplasm/analysis
MH  - Receptor, ErbB-2/*analysis/genetics
MH  - Sensitivity and Specificity
RF  - 16
EDAT- 2001/08/28 10:00
MHDA- 2002/01/31 10:01
CRDT- 2001/08/28 10:00
PHST- 2001/08/28 10:00 [pubmed]
PHST- 2002/01/31 10:01 [medline]
PHST- 2001/08/28 10:00 [entrez]
AID - S0923-7534(19)54467-2 [pii]
AID - 10.1093/annonc/12.suppl_1.s97 [doi]
PST - ppublish
SO  - Ann Oncol. 2001;12 Suppl 1:S97-100. doi: 10.1093/annonc/12.suppl_1.s97.